Ratcliffe Liam 4

What Happened Liam Ratcliffe, a director of Disc Medicine, received a derivative equity award on 2026-06-18 covering 6,212 shares. The grant shows a $0.00 acquisition price (no cash paid) and is reported as an award/grant (derivative), not an exercised option or open-market purchase/sale.

Key Details

• Transaction date: 2026-06-18; Form 4 filed: 2026-06-23.
• Award: 6,212 derivative shares; acquisition price reported as $0.00 (total reported value $0).
• Shares owned after transaction: not specified in the filing.
• Footnote: these underlying shares vest upon the earlier of (i) the Company’s 2027 annual meeting or (ii) the one‑year anniversary of the grant, subject to Ratcliffe’s continued service on the vesting date.
• Transaction type: Award/Grant (code A); this is a compensation equity grant, not a purchase or sale.

Context This filing documents a standard director equity award that vests based on time and continued service. It is a derivative grant (option/restricted equity-like) and was not an exercise or immediate sale, so it does not represent an outright cash investment or divestment by the director. Such awards are commonly used for director compensation and do not by themselves indicate a market view.